2-Carboxy-3,4,5-trihydroxypiperidin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Carboxy-3,4,5-trihydroxypiperidin
• 英文别名: 3,4,5-trihydroxypiperidine-2-carboxylic acid
• 化学式: C₆H₁₁NO₅
• 分子量: 177.16
• InChiKey: ZHFMVVUVCALAMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases
  申请人：Wustman Brandon

  公开号：US20120309788A1

  公开（公告）日：2012-12-06

  The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.

  本发明涉及一种治疗患有阿尔茨海默病的个体的方法，该方法使用药理伴侣增加参与神经节苷脂降解的神经节苷脂酶和/或唾液酸酶酶活性。
• Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
  申请人：Amicus Therapeutics, Inc.

  公开号：US20150374733A1

  公开（公告）日：2015-12-31

  The present invention relates to a method for treating an individual having Cerebral Amyloid Angiopathy by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.

  本发明涉及一种治疗患有脑淀粉样血管病的个体的方法，通过使用药理伴侣增加参与神经节苷脂降解的神经节苷脂酶和/或唾液酸酶酶活性。
• New process for the preparation of nojirimycin and related compounds
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0433978A2

  公开（公告）日：1991-06-26

  The present invention relates to an efficient new route for the preparation of (+)-nojirimycin and (+)-1-deoxynojirimycin which involves the steroselective reductive amination of 1,2-O-isopropylidene-5-oxo-α-D-glucuronolactone. The reductive amination uses particular oximes of the 5-oxo compound (Formula II).

  本发明涉及制备(+)-野尻霉素和(+)-1-脱氧野尻霉素的高效新路线，该路线涉及1,2-O-异亚丙基-5-氧代-α-D-葡萄糖醛酸内酯的立体选择性还原胺化。还原胺化反应使用 5-氧代化合物（式 II）的特定肟。
• Treatment of energy utilization disease
  申请人：Vida Pharma Limited

  公开号：US10842784B2

  公开（公告）日：2020-11-24

  Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.

  所描述的是包含亚氨基糖酸的组合物，用于治疗能量利用疾病（例如代谢综合征，包括与之相关的任何疾病或紊乱，例如中心性肥胖、甘油三酯水平升高和糖尿病，包括 1 型糖尿病、2 型糖尿病和胰岛素抵抗）；从各种植物来源生产所述组合物的工艺，以及基于此的各种产品、化合物、组合物、医疗用途和方法。
• Method for enhancing mutant enzyme activities in gaucher disease
  申请人：Fan Jian-Qiang

  公开号：US20050113415A1

  公开（公告）日：2005-05-26

  Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxynojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.

  提高哺乳动物细胞中与戈谢病有关的酶的活性的方法，方法是施用有效量的葡萄糖脑苷脂酶竞争性抑制剂，以提高该酶的活性。用于该方法的优选化合物是亚氨基糖和相关化合物。特别是，N-烷基-脱氧野尻霉素的C8-12-烷基衍生物、异法戈明化合物和卡尔斯泰金化合物可有效增强葡萄糖脑苷脂酶的活性。